• Hot Tips Archive
Mad Hedge Fund Trader
  • About
  • Store
  • Luncheons
  • Testimonials
  • Free Newsletter / Hot Tips
  • Contact Ussupport@madhedgefundtrader.com
  • Login
  • Search
  • Menu

Are These The New Neuroscience Trailblazers?

Biotech Letter

Aducanumab isn’t going gently into the night.

Positive data from Eli Lilly (LLY) breathed renewed interest in the efforts to find a cure for Alzheimer’s disease, the most common form of dementia and the sixth leading cause of death among Americans.

With 1 in 10 people aged 65 and older suffering from this condition, it’s no wonder that Big Pharma has invested so much in searching for a treatment.

Lilly’s candidate, Trailblazer-ALZ 2, is in its Phase 2 trials. Results showed that the progression of moderate Alzheimer’s disease among patients who took the drug showed a 32% decline compared to a placebo.

In a sector riven by failure and with a potential target market as lucrative as $30 billion annually, investors welcomed Lilly’s news with enthusiasm.

If successful, Trailblazer-ALZ 2 could reach $5 billion in peak sales. As expected, the results boosted Lilly’s stock, with it rising by 14% from $166 to $190.

While the Lilly study is promising, it involved only 272 patients.

This is easily dwarfed by Biogen’s (BIIB) efforts to find a cure for Alzheimer’s. As of last count, the giant biotechnology company’s previous trial for its own drug, Aducanumab, involved over 3,200 patients.

More importantly, Lilly’s Trailblazer-ALZ 2 is projected to hit the market in 2025, while Biogen’s Aducanumab is “ready to go.”

Aducanumab is a monthly infusion designed as a long-term treatment for generally healthy individuals who are beginning to show symptoms of Alzheimer’s disease.

Although this treatment has yet to be approved, the FDA is said to be in favor of its approval.

Outside the US, Biogen has also filed for potential approval in Japan and Europe. All approvals could come by early to mid-2021. 

If approved, Aducanumab is expected to reach $12 billion in peak sales.

While this plan is still up in the air, the $12 billion in sales alone could easily justify the entire company’s current valuation.

Despite the uncertainty, Biogen remains promising thanks to the high potential of the existing drugs in its roster and its R&D unit.

In terms of pipeline, the company has at least 30 active clinical programs. Eight of which are already in Phase 3 and filed, including Aducanumab.

In recent years, Biogen has been focusing on expanding its neuroscience segment.

With over $28 billion potential market size, it no longer comes as a surprise why Biogen is pouring in cash in this particular sector.

Bolstering its efforts in the neuroscience segment, Biogen has recently invested in the Series A round of Atalanta Therapeutics, a Boston-based pioneering neurodegenerative diseases biotechnology company founded in 2018.

Attracted by Atalanta’s research on siRNA, which are molecules that can “silence” genes in the brain, Biogen and another biotechnology bigwig, Genentech (DNA), invested a combined $110 million to get a piece of the action.

Specifically, Biogen signed up to collaborate with Atalanta on treatments for Huntington’s along with several other central nervous system disorders.

As for Genentech, the $73.9 billion valued company’s deal with Atalanta covers Alzheimer’s and Parkinson’s.

In both agreements, Atalanta gets upfront payments, milestones, and royalties.

What we know so far is that Atalanta’s siRNA can silence Huntington’s disease gene for at least six months. It can also alleviate symptoms affecting the spinal cords, but this part of the research has only been done on nonhuman primates.

Biogen, which has a market capitalization of $41.15 billion, has seen its share price fluctuate dramatically due to concerns over its Alzheimer’s drug.

The company withstood significant volatility in 2020, experiencing over 40% price swings in both directions. This is primarily because of the ups and downs of its Aducanumab trials, which heavily swayed the opinion of market participants.

Moving forward, I expect Biogen to have a massive year this 2021.

That’s the upside of this stock.

Even at its midpoint and if major treatments like Aducanumab fail to gain approval, I still anticipate a respectable year for this biotechnology company. That kind of security is worth paying attention to, and it can also signal its capacity to drive strong rewards.

Biogen has been shunned in the past year due to its volatility.

After all, who would want to invest in an unpredictable drug like Aducanumab when there are major stock indices and newcomers like Moderna (MRNA) making record-breaking highs?

For investors willing to look beneath the surface though, Biogen offers so much more than what meets the eye.

aducanumab

January 14, 2021/by Mad Hedge Fund Trader
Tags: (BIIB), (DNA), (LLY), (MRNA)
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-01-14 14:00:372021-01-16 20:46:59Are These The New Neuroscience Trailblazers?
You might also like
October 23, 2019
Moderna's Big Corona Play for a Small Company
August 14, 2020

Archives

  • 2021 (364)
    • March (53)
    • February (154)
    • January (157)
  • 2020 (2067)
    • December (170)
    • November (184)
    • October (169)
    • September (177)
    • August (171)
    • July (169)
    • June (186)
    • May (192)
    • April (196)
    • March (177)
    • February (144)
    • January (131)
  • 2019 (1772)
    • December (132)
    • November (128)
    • October (168)
    • September (128)
    • August (173)
    • July (138)
    • June (113)
    • May (159)
    • April (169)
    • March (169)
    • February (141)
    • January (153)
  • 2018 (1798)
    • December (150)
    • November (157)
    • October (194)
    • September (131)
    • August (150)
    • July (133)
    • June (128)
    • May (162)
    • April (185)
    • March (155)
    • February (153)
    • January (100)
  • 2017 (520)
    • December (96)
    • November (114)
    • October (52)
    • September (47)
    • August (63)
    • July (38)
    • June (52)
    • May (58)
  • 2016 (1369)
    • December (116)
    • November (107)
    • October (133)
    • September (110)
    • August (125)
    • July (98)
    • June (111)
    • May (142)
    • April (119)
    • March (112)
    • February (91)
    • January (105)
  • 2015 (1290)
    • December (98)
    • November (94)
    • October (89)
    • September (106)
    • August (105)
    • July (87)
    • June (72)
    • May (101)
    • April (134)
    • March (145)
    • February (122)
    • January (137)
  • 2014 (1490)
    • December (112)
    • November (107)
    • October (151)
    • September (120)
    • August (110)
    • July (123)
    • June (109)
    • May (117)
    • April (129)
    • March (153)
    • February (130)
    • January (129)
  • 2013 (1601)
    • December (125)
    • November (176)
    • October (172)
    • September (162)
    • August (131)
    • July (140)
    • June (114)
    • May (123)
    • April (146)
    • March (123)
    • February (87)
    • January (102)
  • 2012 (781)
    • December (23)
    • November (18)
    • October (24)
    • September (78)
    • August (90)
    • July (67)
    • June (68)
    • May (97)
    • April (88)
    • March (86)
    • February (77)
    • January (65)
  • 2011 (449)
    • December (59)
    • November (73)
    • October (23)
    • September (31)
    • August (44)
    • July (34)
    • June (14)
    • May (43)
    • April (20)
    • March (42)
    • February (29)
    • January (37)
  • 2010 (356)
    • December (32)
    • November (45)
    • October (45)
    • September (51)
    • August (58)
    • July (43)
    • May (6)
    • April (1)
    • March (35)
    • February (17)
    • January (23)
  • 2009 (252)
    • December (20)
    • November (18)
    • October (22)
    • September (20)
    • August (15)
    • July (19)
    • June (20)
    • May (20)
    • April (19)
    • March (22)
    • February (19)
    • January (38)
  • 2008 (420)
    • December (38)
    • November (36)
    • October (46)
    • September (40)
    • August (34)
    • July (38)
    • June (36)
    • May (42)
    • April (42)
    • March (28)
    • February (40)

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2021. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
January 14, 2021 January 14, 2021
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only